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It is becoming increasingly apparent that the tumor microenvironment plays an important
role in the progression of cancer. The microenvironment may promote tumor cell survival
and proliferation or, alternatively may induce tumor cell apoptosis.Toll-like receptors (TLRs)
are transmembrane proteins, expressed on immune cells and epithelial cells, that recog-
nize exogenous and endogenous macromolecules. Once activated, they initiate signaling
pathways leading to the release of cytokines and chemokines, which recruit immune cells
inducing further cytokine production, the production of angiogenic mediators and growth
factors, all of which may influence tumor progression. This paper examines the actions
of TLRs in carcinogenesis with particular emphasis on their role in oral squamous cell
carcinoma.
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INTRODUCTION
Toll-like receptors (TLRs) are cell surface or intracellular trans-
membrane proteins that are expressed on sentinel cells of the
immune system such as macrophages and dendritic cells. In
addition, they are present on non-immune cells such as ker-
atinocytes of skin (1) and oral mucosa (2), gastrointestinal (3),
and female reproductive tract lining (4). On these lining epithe-
lia, TLRs act as sensors where they recognize pathogens and are
activated when the epithelium is disturbed. Microbial pathogens
are characterized by specific arrangements of molecules known
as pathogen-associated molecular patterns (PAMPs), which can
be recognized by pattern-recognition receptors (PRRs), includ-
ing TLRs. TLRs are capable of recognizing bacterial, viral, fungal,
and protozoal components. While their role as PRRs is important
in host defense, it is their ability to regulate innate and adaptive
immune responses via information from surface epithelial cells
that is their most potent role, along with their ability to recruit
immune cells (5).
Once activated, TLRs trigger co-ordinated expression of genes
involved in specific signaling pathways in the regulation of innate
and adaptive immunity and tissue repair and regeneration. Their
cytoplasmic domain has extensive homology with the interleukin
(IL)-1 receptor family and is known as the Toll-IL receptor
(TIR) domain (6). With binding of ligand to TLRs, there is acti-
vation of signaling transduction pathways involving TIR with
coupling to adaptor molecules including myeloid differentiation
factor 88 (MyD88), TIR domain-containing protein (TIRAP), and
TIR domain-containing adaptor inducing interferon-β-related
adaptor molecule (TRAM). This potentially leads to the activa-
tion of two main pathways, the MyD88-dependent (used by all
TLRs except TLR3) and the MyD88-independent TRAM/TRIF
pathway (used by TLR3 and some signals of TLR4) (5). Sig-
naling through the MyD88 pathway leads to activation and
translocation from the cytoplasm to the nucleus of the tran-
scription factor nuclear factor-κB (NF-κB). There it binds to
the promoter region of a variety of immune and inflammatory
genes leading to the transcription of inflammatory and anti-
inflammatory cytokine genes, e.g., tumor necrosis factor (TNF)-
α and IL-6 (3, 4, 7). Activation of the TRAM/TRIF pathway
leads to the production of type 1 interferons. In this manner,
TLRs regulate the production of cytokines, opsonization, coag-
ulation cascades, complement activation, and upregulation of
co-stimulatory molecules on antigen presenting cells (4, 8, 9).
Alteration to TLR genes, as occurs with single-nucleotide poly-
morphisms (SNPs), may interfere with the function of TLRs
and shift the balance of the cytokines produced (10). A fur-
ther important function of TLRs is the induction of apoptosis
through the expression of anti-apoptotic proteins and apoptosis
inhibitors (11).
Initially, study of TLRs in pathology was concentrated on their
association with microbial pathogens. It is increasingly appar-
ent that TLRs also recognize damage/danger-associated molecular
patterns (DAMPs), endogenous molecules released from dam-
aged and dying cells. DAMPs include heat shock proteins (HSP),
nucleic acids, fibrinogen, and high-motility group box-1 protein
(HMGB1) (3, 12, 13). DAMPs can be released from cells that have
been affected by various stimuli and have entered a potentially
neoplastic phase, as well as from cells that have undergone malig-
nant transformation (14, 15). This has led to a large number of
studies investigating the role of TLRs in the pathogenesis of a range
of malignant neoplasms. The association of TLRs with neoplasia
will be discussed below, with particular emphasis on two points:
(a) how this information can be used to advance our knowledge of
the association between TLRs, inflammation, and cancer, particu-
larly oral squamous cell carcinoma (OSCC) and (b) how it can be
used to develop new therapeutic strategies.
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INFLAMMATION, TLRs, AND CANCER
Infection is an important cause of cancer, causing approximately
one in five malignancies worldwide (16, 17). Infection with the
bacterium Helicobacter pylori leads to an elevated risk of develop-
ing gastric adenocarcinoma and gastric lymphoma, infection with
particular types of human papilloma virus (HPV) leads to cervical
cancer, tonsillar carcinoma, and some cases of OSCC, and chronic
hepatitis B and C infections leads to hepatocellular carcinoma (16–
19). The herpesvirus, Epstein–Barr virus (EBV), is implicated in
a range of malignancies including Burkitt’s lymphoma, Hodgkin
lymphoma, and nasopharyngeal carcinoma, and another member
of the herpesvirus family, human herpesvirus 8, is a causal factor
in Kaposi sarcoma (17, 18). The response of TLRs to these infec-
tions is crucial to the evolution of the infection and possibly to the
transformation to malignancy, but a full review of infection and
cancer is beyond the scope of this review. Instead, we intend to
concentrate on the role of TLRs in tumor development, whether
or not the tumor was associated with prior infection. The modula-
tion of the inflammatory process by TLRs is a key factor in tumor
development and progression, inducing both tumor-promoting
and anti-tumor responses (15, 20). TLRs have also been shown
to play a crucial role in tissue repair and regeneration following
injury, particularly in relation to epithelial regeneration and myofi-
broblast activation (20–22) These processes may be mediated by
TLRs providing pro-survival signals and by preventing apopto-
sis and hence may dictate the balance between satisfactory and
maladaptive wound healing (21, 22).
Genetic disruption of TLRs and adaptor molecules of the
TLR pathway has been associated with tumor development and
progression in mice (23, 24). TLRs mediate both pro- and anti-
tumorogenic pathways, the so-called double-edged sword (25,
26) – see Figure 1. DAMP activation of TLRs expressed on tumor
cells initiates cascades that mediate the release of cytokines and
chemokines from the tumor cells which, in turn, recruit immune
cells leading to upregulation of NF-κB signaling and subsequent
release of additional cytokines, pro-angiogenic mediators, growth
factors, and anti-apoptotic proteins that continue to promote
tumor survival and progression (15, 20, 27). It should be noted,
however, that the role TLRs play in relation to apoptosis is complex
and variable with evidence that they can prevent apoptosis, but
also have pro-apoptotic activity through a range of mechanisms
(28, 29).
The nuclear transcriptional factor NF-κB is constitutively
expressed in many human cancers (30, 31), and its signaling path-
way has a critical role in carcinogenesis (32, 33). Mutations in
NF-κB signaling molecules have been reported in a range of malig-
nancies, including human B-cell lymphomas (34). NF-κB is likely
to be linked to this process through its ability to induce expression
of adhesion molecules, MMPs, and pro-inflammatory cytokines,
which creates a microenvironment favorable for cancer cell sur-
vival (7, 32). A potential feedback loop between pro-inflammatory
cytokines such as TNF-α and NF-κB has been suggested and this
links the role of NF-κB in inflammation and cancer (32, 35).
It has also been suggested that NF-κB contributes to genomic
instability through its anti-apoptotic activities, in addition to the
suppression of apoptosis in tumor cells,which promotes tumor cell
survival (36, 37). The NF-κB signaling pathway is an essential anti-
apoptotic pathway that has been shown to control the expression
of anti-apoptotic genes and restrict the activation of pro-apoptotic
pathways (20).
It has been suggested that the amplitude and duration of
TLR activation may be instrumental in tumor development, with
chronic low-grade activation favoring a tumor-promoting pro-
inflammatory state and with high dose therapeutically induced
TLR activation favoring an anti-tumor response (20). Vari-
ous TLRs play different roles in carcinogenesis. TLR4 shows
FIGURE 1 | Diagram showing howTLRs can mediate pro- and anti-tumor pathways.
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pro-tumorogenic effects, with mice deficient in TLR4 at reduced
risk of developing gastrointestinal and hepatocellular cancer (23,
38). This effect has been shown to be due to augmentation of the
inflammatory response via activation of the NF-κB, and cyclooxy-
genase (Cox)-2/prostaglandin E2 signaling pathways (23, 38). The
TLR4 pro-tumorogenic activity is mainly due to its expression on
tumor cells where it mediates resistance of tumor cells to dam-
age induced by cytotoxic T lymphocytes (25, 37), but triggering of
TLR4 expressed on immune cells is also important in tumor devel-
opment and progression (37). Release of HSP from tumor cells can
lead to activation of TLR4 on tumor-associated macrophages, in
turn mediating NF-κB activation of tumor cells (39). While TLR4
is predominately pro-tumorogenic, it can induce the production
of interferons contributing to an anti-tumor response (37).
Both TLR3 and TLR5 are also pro-tumorogenic with their
signals mediating tumor invasion and metastasis by enhancing
cell migration, but, like TLR4, also have an anti-cancer effect in
some situations (14, 40, 41). TLR9 expressed on tumor cells has
been associated with increased cell proliferation and increased
invasion potential (42,43). On the other hand,TLR2 signaling sup-
pressed cancer development and assisted tumor regression (37).
Lack of TLR2 led to increased cell proliferation and decreased
apoptosis in a mouse model of colorectal cancer (24). The mech-
anism by which TLR2 induces tumor suppression is thought to
be mediated through tumor-derived HMGB1, which activates
TLR2 in dendritic cells in the tumor microenvironment, leading
to tumor regression (44). While most reports describe the anti-
tumor functions of TLR2, opposing results have been reported
in a context-dependent manner with TLR2 playing an important
tumor-promoting role in gastric cancer (20, 45, 46).
ASSOCIATION OF TLRs WITH ORAL CANCER
Oral and pharyngeal cancer is the sixth most common cancer in
the world, with oral cancer having an annual estimated incidence
of approximately 275,000 globally and with two-thirds of cases
occurring in developing countries (47). Despite advances in diag-
nosis and improved treatment strategies, OSCC continues to have
a poor 5-year survival rate, and conventional treatment modalities
of surgery and radiotherapy are associated with significant mor-
bidity (48). OSCC, like other cancers, develops in an immune
cell-rich environment, where inflammatory cells in the tumor
microenvironment establish an anti-tumor response by secret-
ing pro-inflammatory cytokines. At the same time, the cancer
cells may induce various mechanisms suppressing the anti-tumor
response, such as regulating a network of suppressive cytokines
and the recruitment of suppressive regulatory T-cells (Tregs).
Studies have shown TLRs, particularly TLR2, play a role in Treg
expansion and their suppressive capacity (49). More keratinocytes
in OSCC expressed TLR2 than keratinocytes in control epithelium
(50). Further research in our laboratory has confirmed the pres-
ence of TLR2+ cells within the OSCC microenvironment (51).
The cells that were expressing TLR2 were large and morphologi-
cally consistent with macrophages or DC (Figure 2). The presence
of TLR2+FoxP3+ cells within the OSCC immune cell infiltrate
was noted, an observation previously unreported in OSCC. This
is important, particularly in relation to cancer immumotherapy.
Cells expressing TLRs could potentially be modulated to shift
FIGURE 2 | Photomicrograph showingTLR2+ cells with a dusky red cell
membrane and cytoplasmic staining (black arrow) with the
morphology of macrophages in OSCC (×100, bar: 100µm).
the environment toward a Th1 environment, thus stimulating the
pro-inflammatory process.
Head and neck cancer cell lines and OSCC tissue specimens
were found to express TLR3, and this was associated with high
levels of expression and activity of NF-κB (40, 41, 52). Inhibi-
tion of TLR3 by siRNA resulted in decreased expression of the
NF-κB-regulated oncogene c-myc and decreased cell proliferation
(53). Stimulation of TLR3+ OSCC tumor cells promoted their
migration, and TLR3 expression was found to be significantly cor-
related with poor differentiation and perineural invasion in OSCC
(40). Further, activation of TLR3 was found to induce apoptosis in
OSCC cells, most likely mediated by activation of the IRF/IFN-β
signaling pathway (41).
TLR4 and MyD88 were expressed in human OSCC cell lines and
expression level correlated with tumor differentiation, with higher
expression in more well-differentiated carcinomas (54). Expres-
sion of TLR4 increased with increasing degrees of oral epithelial
dysplasia (55) and distribution of TLR4 extended from the basal
layer through the stratum spinosum as dysplasia progressed.
TLR5 expression was more pronounced in tongue cancer cells
than in adjacent apparently normal epithelium and high expres-
sion levels of TLR5 predicted a poorer prognosis (14). While,
overall, there was relatively little TLR9 expression in dysplastic oral
tissue, there was significantly more than in normal oral mucosa
(55) and increased expression of TLR9 had earlier been found to
correlate with increased tumor cell proliferation in OSCC (56, 57).
Subsequent reports suggested that TLR9 directly promoted cancer
cell invasion (58).
THERAPEUTIC POSSIBILITIES
Since advances in conventional treatments have not appreciably
increased the survival rate of OSCC (48), attention has turned
to immunotherapy including investigation of drugs that interfere
with the NF-κB and TLR signaling pathways. Interference with
these pathways has implications for many of the important steps
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in carcinogenesis including the relationship between TLR+ cells
and regulatory T-cells, and subsequent cytokine production, the
effects on dendritic cells and macrophages, the effects on apopto-
sis and on cell proliferation. Acetylsalicylic acid has been shown to
reduce the long-term risk of developing some cancers, and, while
the precise mechanisms of action remain uncertain, there is evi-
dence that modulation of the NF-κB signal transduction pathway
by aspirin and other non-steroidal anti-inflammatory agents is an
important mechanism in inducing apoptosis in neoplastic epithe-
lial cells (59, 60). Meyer et al. (33) found aspirin and another
COX-2 inhibitor, celecoxib inhibited NF-κB in head and neck can-
cer cell lines. Both selective and non-selective COX-2 inhibitors
reduced cancer incidence and invasion score in an animal model
of experimental oral carcinogenesis, although the potential mech-
anisms of actions of the drugs were not discussed in detail (61).
Drugs other than COX inhibitors have been shown to interfere
with the NF-κB pathway in various malignancies, e.g., glucocor-
ticoids, while being pro-apoptotic in leukemia and lymphomas,
have been found to enhance survival of some breast cancer cell
lines through promoting NF-κB transcriptional activity leading to
upregulation of c-Myc and enhanced anti-apoptotic function (62,
63). Sulfasalazine can act as a NF-κB inhibitor leading to reduced
proliferation and enhanced apoptosis of esophageal cancer cell
lines (64) and has be shown to induce autophagic cell death in
oral cancer cell lines, although this was thought to be mediated via
Akt and ERK pathways (65).
It is likely that at least some of the effects on NF-κB are medi-
ated through various TLR pathways. TLR4 induced resistance to
cisplatin-induced apoptosis in OSCC cell lines (54). The authors
suggested that activation of TLR4 and its signaling pathways was a
mechanism to explain the resistance that develops in patients with
OSCC, after a good initial response to that drug. The potential use
of the immunostimulatory properties of TLR agonists, particu-
larly TLR2, TLR3, TLR4, TLR7/8, and TLR9, has been investigated
in cancer immunotherapy (66). Sutmuller and colleagues (49)
showed that TLR2 controls the expansion and suppression of Tregs
by directly acting on these cells. They also showed that there was
a temporary loss of Treg suppressive function when bound to a
TLR2 ligand; concurrently, this could also induce the prolifera-
tion of CD4+CD25+ Tregs. Subsequently, it was shown that TLR2
agonists enhanced the suppressive effect of Tregs (67). This obser-
vation may explain in part the failure of some immunotherapies,
in particular, the use of TLR agonists as anti-cancer treatment.
By inducing apoptosis, necrosis, and activating immune and den-
dritic cells, TLR agonists induce an anti-tumor effect (68). Topical
imiquimod, a synthetic TLR7 agonist, that has been shown to
induce temporary regression of breast cancer in an animal model
(69) and has had some success in the management of varying types
of dysplastic skin lesions and superficial skin cancers (70, 71). It
has been shown to reduce the degree of dysplasia in a mouse model
of oral cancer (although there was no long-term follow-up) (72)
and in OSCC cell lines (73).
Although much anticipated, the outcome of TLR agonist ther-
apeutic trials has been disappointing (74). Clinical studies with
TLR agonists have shown expansion of Tregs within the tumor
environment, which may enhance tumor progression, although
some trials have shown reduction in tumor size (69, 75). This
has earned TLRs the connotation of a “double-edged sword” by
most workers who investigated their functionality (76, 77). Hence,
the therapeutic use of TLR agonists needs to be undertaken with
caution. TLR antagonists are structural analogs of agonists, which
bind to TLRs and do not induce signal transduction. This prevents
the agonistic action of TLR ligands responsible for the induction
of inflammatory responses (78, 79). These agents can be used to
gain a greater understanding of the effectiveness of TLR agonist
therapy in animal models of cancer.
To overcome the “double-edged sword,” manipulation of the
“un-touched” TLR+ cells within the OSCC tumor microenviron-
ment is required. The key factors lie in the balance of the cytokine
network within the tumor environment. It is crucial to look into
the expression of various cytokines at different stages of OSCC.
Inhibition of NF-κB in head and neck cancer cell lines was asso-
ciated with downregulation of TLR3 and decreased levels of IL-6
and IL-8 and the expected shift to a TH2 microenvironment, typi-
cal in head and neck squamous cell carcinomas did not occur (33).
Modulation of macrophages or DCs using the cytokine network
is necessary to overcome potential immune suppression, before
they are recruited to become tolerogenic cells. The administra-
tion of agents that interfered with TLR3 signaling in a mouse
model of lung cancer led to tumor regression by converting tumor-
supporting macrophages to tumor suppressors (80). Again, the
presence of “un-touched” TLR+ macrophages supports the theory
that reversal or “resurgence” by the immune system is important
in fighting back against the tumor escape mechanisms.
The association of TLRs with tumor cell proliferation is another
potential area for therapeutic intervention. TLR3 (52) and TLR9
(56) have been associated with cell proliferation in head and neck
cancer, and Ruan et al. (58) suggested that the use of anti-TLR9
agents may reduce tumor cell proliferation in OSCC as well as
reducing metastatic potential.
Although complete molecular mechanisms remain to be deter-
mined, there are a variety of TLR pathways that may provide
therapeutic targets for the management of OSCC.
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